ProCE Banner Activity

CE

Optimal Therapeutic Sequencing in Relapsed/Refractory CLL for Pharmacists

Video

In this on-demand webcast, experts discuss the importance of determining the most effective treatment sequence for patients with chronic lymphocytic leukemia (CLL) who have either relapsed or are refractory to initial therapies. 

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: December 11, 2024

Expiration: June 10, 2025

Share

Faculty

Karen M. Fancher

Karen M. Fancher, PharmD, BCOP

Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist – Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania

Anthony J. Perissinotti

Anthony J. Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

Caitlin R. Rausch

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for pharmacists and other healthcare professionals globally who care for patients with chronic lymphocytic leukemia.

Program Learning Goal

This activity aims to improve learners' knowledge, competence, and performance to optimize clinical outcomes for patients with chronic lymphocytic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Integrate new and emerging data on noncovalent BTK inhibitors into the management of patients with relapsed/refractory CLL/SLL

  • Plan therapeutic strategies for patients with relapsed/refractory CLL/SLL based on current guidelines, available clinical evidence, and expert recommendations

  • Proactively select and sequence treatment regimens and long-term treatment plans for individual patients with CLL/SLL to optimize clinical benefit

  • Assess patients with relapsed/refractory CLL/SLL who have progressed on or following covalent BTK inhibitor therapy for resistance mutations

  • Implement effective interprofessional team processes and workflows to promote adherence to and persistence with oral anticancer therapy to ensure optimal clinical outcomes in patients with relapsed/refractory CLL/SLL

  • Mitigate and manage treatment-related and disease-related adverse events in patients with relapsed/refractory CLL/SLL

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Karen M. Fancher, PharmD, BCOP

Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Clinical Pharmacy Specialist – Oncology
University of Pittsburgh Medical Center Passavant
Pittsburgh, Pennsylvania

Karen M. Fancher, PharmD, BCOP: consultant/advisor/speaker: AstraZeneca.

Anthony J. Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

Anthony J. Perissinotti, PharmD, BCOP: consultant/advisor/speaker: AbbVie, Amgen, Servier.

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 11, 2024, through June 10, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-24-337-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.